MCID: FBR009
MIFTS: 45

Fibrous Dysplasia malady

Categories: Rare diseases, Bone diseases

Aliases & Classifications for Fibrous Dysplasia

About this section

Aliases & Descriptions for Fibrous Dysplasia:

Name: Fibrous Dysplasia 11 48 50 13 68
 
Fibrous Dysplasia of Bone 48

Classifications:



External Ids:

Disease Ontology11 DOID:0080031
ICD1030 M85.0

Summaries for Fibrous Dysplasia

About this section
NIH Rare Diseases:48 Fibrous dysplasia is a skeletal disorder that is characterized by the replacement of normal bone with fibrous bone tissue. it may involve one bone (monostotic) or multiple bones (polyostotic). fibrous dysplasia can affect any bone in the body. the most common sites are the bones in the skull and face, the long bones in the arms and legs, the pelvis, and the ribs. though many individuals with this condition do not have any symptoms, others may have bone pain, abnormally shaped bones, or an increased risk of fractures (broken bones). this condition can occur alone or as part of a genetic disorder, such as mccune-albright syndrome. while there is no cure for fibrous dysplasia, the symptoms can be treated. medications known as bisphosphonates can reduce pain and surgery may be indicated for fractures or to correct misshapen bones.  last updated: 4/4/2016

MalaCards based summary: Fibrous Dysplasia, also known as fibrous dysplasia of bone, is related to monostotic fibrous dysplasia and mccune-albright syndrome, somatic, mosaic. An important gene associated with Fibrous Dysplasia is GNAS (GNAS Complex Locus), and among its related pathways are Development_Hedgehog and PTH signaling pathways in bone and cartilage development and Osteoblast Signaling. Affiliated tissues include bone, bone marrow and myeloid, and related mouse phenotypes are Increased shRNA abundance and neoplasm.

Disease Ontology:11 A bone remodeling disease that results in the destruction of normal bone and replacing it with fibrous bone tissue.

Related Diseases for Fibrous Dysplasia

About this section

Diseases related to Fibrous Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 195)
idRelated DiseaseScoreTop Affiliating Genes
1monostotic fibrous dysplasia12.4
2mccune-albright syndrome, somatic, mosaic12.0
3panostotic fibrous dysplasia12.0
4fibrous dysplasia/mccune-albright syndrome12.0
5osteofibrous dysplasia11.6
6mazabraud syndrome11.5
7cherubism11.2
8congenital tricuspid stenosis10.3GH1, PRL
9intermittent squint10.3GH1, PRL
10glaucoma, hereditary adult type 1a10.3GH1, PRL
11olfactory nerve neoplasm10.2GH1, PRL
12sarcomatosis10.2BGLAP, SPARC
13epilepsy, idiopathic generalized 1410.2BGLAP, FGF23
14grin2a-related speech disorders and epilepsy10.2GH1, GNAS, PRL
15critical congenital heart disease10.2GH1, IGF1
16microtia, hearing impairment, and cleft palate10.2GH1, IGF1
17serous cystadenocarcinoma10.2BGLAP, SPARC
18spondylometaphyseal dysplasia, megarbane-dagher-melike type10.2GH1, IGF1
19aneurysmal bone cysts10.2
20fibroma10.2
21aneurysm10.2
22ossifying fibroma10.2
23pemphigus vegetans10.2GH1, SST
24african histoplasmosis10.2PRL, SST
25dacryoadenitis10.2IGF1, PRL
26primary effusion lymphoma10.2GH1, GNAS, IGF1
27caudal regression syndrome10.1GH1, IGF1, PRL
28adult ependymoblastoma10.1BGLAP, CALCA
29acth-independent macronodular adrenal hyperplasia10.1BGLAP, GNAS, SPARC
30mucopolysaccharidosis type vi10.1GH1, IGF1, PRL
31hypophosphatasia, adult10.1BGLAP, CALCA
32ovarian insufficiency due to fsh resistance10.1BGLAP, GNAS, SPARC
33x-linked hereditary ataxia10.1FGF23, IBSP
34extragonadal nonseminomatous germ cell tumor10.1PRL, SST
35capillary lymphangioma10.1GH1, IGF1, PRL
36cervix squamous papilloma10.1GH1, IGF1, PRL
37epileptic encephalopathy, early infantile, 2410.1GH1, IGF1
38hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy10.1GH1, IGF1, PRL
39cockayne syndrome type i10.1CALCA, PRL
40vaginal adenoma10.1IGF1, SST
41hypogonadism cardiomyopathy10.1CALCA, GH1
42cervicitis10.1
43nonparalytic poliomyelitis10.1PRL, SST
44mesenchymal cell neoplasm10.1BGLAP, CALCA, GNAS
45extrahepatic bile duct adenocarcinoma10.1BGLAP, GH1, IGF1
46cerebral hemisphere lipoma10.1GH1, PRL, SST
47iliac vein thrombophlebitis10.1APC, PRL
48thoracic benign neoplasm10.1CDC73, GNAS, SPARC
49wells-jankovic syndrome10.1CALCA, SST
50pulmonary neuroendocrine tumor10.1GH1, PRL, SST

Graphical network of the top 20 diseases related to Fibrous Dysplasia:



Diseases related to fibrous dysplasia

Symptoms & Phenotypes for Fibrous Dysplasia

About this section

GenomeRNAi Phenotypes related to Fibrous Dysplasia according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00327-A9.3APC, BGLAP, CALCA, GH1

MGI Mouse Phenotypes related to Fibrous Dysplasia according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.9APC, GNAS, IGF1, PRL, SPARC
2MP:00053718.8APC, FGF23, GNAS, IBSP, IGF1, SPARC
3MP:00107718.1APC, CDC73, FGF23, GNAS, IGF1, PRL
4MP:00053907.4APC, FGF23, GNAS, IBSP, IGF1, SPARC
5MP:00053877.2APC, CDC73, FGF23, GNAS, IBSP, IGF1

Drugs & Therapeutics for Fibrous Dysplasia

About this section

Drugs for Fibrous Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Etidronic acidapprovedPhase 2, Phase 3827414-83-7, 2809-21-43305
Synonyms:
(1-Hydroxyethylene)diphosphonic acid
(1-Hydroxyethylidene)bis(phosphonic acid)
(1-Hydroxyethylidene)bisphosphonic acid
(1-Hydroxyethylidene)diphoshonic acid
(1-Hydroxyethylidene)diphosphonic acid
(1-hydroxy-1-phosphonoethyl)phosphonic acid
(1-hydroxy-ethylidene)diphosphonic acid
(1-hydroxyethane-1,1-diyl)bis(phosphonic acid)
(Hydroxyethylidene)diphosphonic acid
0-02-00-00171 (Beilstein Handbook Reference)
1,1,1-Ethanetriol diphosphonate
1-HYDROXY-1,1-DIPHOSPHONOETHANE
1-Hydroxy-1,1-diphosphonoethane
1-Hydroxyethane-1,1,-diphosphonic acid
1-Hydroxyethane-1,1-bisphosphonic acid
1-Hydroxyethane-1,1-diphosphonate
1-Hydroxyethane-1,1-diphosphonic acid
1-Hydroxyethanediphosphonic acid
1-Hydroxyethylidene 1,1-diphosphonic acid
1-Hydroxyethylidene-1,1-biphosphonate
1-Hydroxyethylidene-1,1-bisphosphonate
1-Hydroxyethylidene-1,1-diphosphonic acid
1-Hydroxyethylidenediphosphonic acid
1-hydroxyethane 1,1-diphosphonic acid
1000SL
100511-44-2
103736-66-9
106908-76-3
129130-42-3
138360-84-6
14860-53-8 (tetra-potassium salt)
192526-55-9
2809-21-4
303177-33-5
51888-66-5
54342_ALDRICH
54342_FLUKA
66216-98-6
853028-38-3
85985-26-8
86159-18-4
AC1L1FMT
Acetodiphosphonic acid
Acide etidronique
Acide etidronique [INN-French]
Acido etidronico
Acido etidronico [INN-Spanish]
Acidum etidronicum
Acidum etidronicum [INN-Latin]
BPBio1_000997
BRN 1789291
BSPBio_000905
Bio-0708
C07736
CHEBI:170675
CHEBI:4907
CHEMBL871
CID3305
 
Cintichem Technetium 99m Hedspa
D02373
DB01077
Dequest 2010
Dequest 2015
Dequest Z 010
Didronel
Didronel IV
Diphosphonate (base)
EHDP
EINECS 220-552-8
Ethane-1-hydroxy-1,1-bisphosphonate
Ethane-1-hydroxy-1,1-bisphosphonic acid
Ethane-1-hydroxy-1,1-diphosphonate
Ethane-1-hydroxy-1,1-diphosphonic acid
Etidronate
Etidronate Disodium
Etidronic acid
Etidronic acid (USAN/INN)
Etidronic acid [USAN:INN:BAN]
Etidronic acid monohydrate
Etidronsaeure
Etidronsäure
Ferrofos 510
H0587
H6773_ALDRICH
H6773_SIGMA
HEDP
HSDB 5898
Hydroxyethane-1,1-diphosphonic acid
Hydroxyethanediphosphonic acid
I14-1271
Jsp005415
LS-106637
MLS002207267
MLS002695948
MPI Stannous Diphosphonate
MolPort-001-786-542
NCGC00159352-02
NSC 227995
NSC227995
Osteoscan
Oxyethylidenediphosphonic acid
Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester
Prestwick0_000863
Prestwick1_000863
Prestwick2_000863
Prestwick3_000863
RP 61
SMR000038750
SPBio_002826
STK721995
Turpinal SL
UNII-M2F465ROXU
acide étidronique
acidum etidronicum
ethane-1-hydroxy-1,1-bisphosphonic acid
etidronate
ácido etidrónico
2Risedronate SodiumPhase 2, Phase 398115436-72-1
3Bone Density Conservation AgentsPhase 2, Phase 33376
4DiphosphonatesPhase 2, Phase 3450
5calcium channel blockersPhase 2, Phase 31985
6Calcium, DietaryPhase 2, Phase 35713
7Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 2, Phase 113168
8HormonesPhase 3, Phase 2, Phase 114415
9Hormone AntagonistsPhase 3, Phase 2, Phase 113180
10
AlendronateapprovedPhase 2162121268-17-5, 66376-36-12088
Synonyms:
(4-Amino-1-hydroxybutylidene)bisphosphonic acid
(4-Amino-1-hydroxybutylidene)diphosphonic acid
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
(4-amino-1-hydroxybutylidene)bisphosphonic acid
121268-17-5 (mono-hydrochloride salt, trihydrate)
1yhm
4-Amino-1-hydroxybutane-1,1-diphosphonate
4-Amino-1-hydroxybutane-1,1-diphosphonic Acid
4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid)
4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
4-amino-1-hydroxybutane-1,1-diphosphonic acid
66376-36-1
ABDP
AC1L1CW3
AKOS001015793
ALENDRONATE SODIUM
ALENDRONIC ACID
Acide Alendronique
Acide Alendronique [INN-French]
Acide alendronique
Acide alendronique [INN-French]
Acido Alendronico
Acido Alendronico [INN-Spanish]
Acido alendronico
Acido alendronico [INN-Spanish]
Acidum Alendronicum
Acidum Alendronicum [INN-Latin]
Acidum alendronicum
Acidum alendronicum [INN-Latin]
Adronat
 
Alendronate
Alendronate Sodium
Alendronate sodium hydrate
Alendronic acid
Alendronic acid (INN)
Alendronic acid [INN:BAN]
Alendros
Arendal
BIDD:GT0180
C07752
CHEBI:2567
CHEMBL870
CID2088
D07119
DB00630
Fosamax
Fosamax Plus D
HSCI1_000337
LS-106421
MK 217
MK-217
MolPort-000-421-410
NCGC00096054-01
NCGC00096054-03
NCGC00096054-04
Onclast
Oprea1_422906
Phosphonic acid, (4-amino-1-hydroxybutylidene)bis
SPECTRUM1505166
ST50036159
UNII-X1J18R4W8P
alendronate
bisphosphonate, 65
11
TestolactoneapprovedPhase 24968-93-413769
Synonyms:
(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione
(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione
.DELTA.1-Dehydrotestolactone
.DELTA.1-Dehydrotestololactone
.DELTA.1-Testololactone
1 Dehydrotestolactone
1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone
1,2-Dehydrotestololactone
1,2-didehydrotestololactone
1-Dehydrotestolactone
1-dehydrotestololactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI)
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone
13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid δ-lactone
17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione
17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione
2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone
3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone
968-93-4
AC1L22FS
Bristol Myers Squibb Brand of Testolactone
Bristol-Myers Squibb Brand of Testolactone
C02197
C19H24O3
CHEBI:9460
CHEMBL1571
CID13769
D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione
D-homo-17a-oxaandrosta-1,4-diene-3,17-dione
D00153
 
D013738
DB00894
Delta(1)-testololactone
Delta-1-testololactone
EINECS 213-534-6
Fludestrin
HSDB 3255
LMST02020084
LS-102968
MolPort-004-286-011
NCI60_001908
NSC 23759
NSC-12173
NSC23759
SQ 9538
SQ-9538
TESLAC (TN)
Teolit
Teslac
Teslak
Testolacton
Testolactona
Testolactona [INN-Spanish]
Testolactone
Testolactone (USP/INN)
Testolactone [USAN:INN]
Testolactonum
Testolactonum [INN-Latin]
Testolattone
Testolattone [DCIT]
Testolattone [Dcit]
UNII-6J9BLA949Q
ZINC04081771
delta(1)-Dehydrotestolactone
delta(1)-Testolactone
delta(1)-testololactone
Δ1-testololactone
12
Anastrozoleapproved, investigationalPhase 2279120511-73-12187
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
AC-4234
AC1L1D49
Anastrazole
Anastrole
Anastrozol
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
AstraZeneca brand of anastrozole
C08159
C090450
C17H19N5
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
 
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD-1033
ZD1033
ZINC00000941
Zeneca ZD 1033
Zeneca brand of anastrozole
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
anastrozole
13
Fulvestrantapproved, investigationalPhase 2202129453-61-8104741, 17756771
Synonyms:
(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
129453-61-8
7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
AC-4693
AC1L2XEN
AstraZeneca brand of fulvestrant
BIDD:ER0348
BIDD:PXR0136
C070081
C32H47F5O3S
CCRIS 8741
CHEBI:404798
CHEMBL1358
CID104741
D01161
DB00947
Faslodex
Faslodex (TN)
 
Faslodex(ICI 182,780)
Faslodex, ICI 182780, Fulvestrant
Fulvestrant
Fulvestrant (JAN/USAN/INN)
Fulvestrant [USAN]
HMS2090N22
HSDB 7658
I06-1109
ICI 182,780
ICI 182,789
ICI-182780
Ici 182780
LS-64781
NCGC00164789-02
NSC719276
S1191_Selleck
UNII-22X328QOC4
ZD 182780
ZD-182780
ZD-9238
ZM 182780
ZM-182780
fulvestrant
nchembio.168-comp5
nchembio.76-comp5
nchembio775-comp4
14Estrogen AntagonistsPhase 2, Phase 11349
15Steroid Synthesis InhibitorsPhase 2, Phase 11763
16Aromatase InhibitorsPhase 2, Phase 1826
17EstrogensPhase 2, Phase 12542
18Antineoplastic Agents, HormonalPhase 25592
19Estrogen Receptor AntagonistsPhase 2194
20
Letrozoleapproved, investigationalPhase 1397112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
 
D00964
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
21
Histamineapproved, investigational105075614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-(4-imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
4-imidazoleethylamine
5-Imidazoleethylamine
5-imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminoethylglyoxaline
beta-aminoethylimidazole
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
22Neurotransmitter Agents18340
23
Histamine Phosphate104951-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
 
EINECS 200-118-4
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ

Interventional clinical trials:

(show all 17)
idNameStatusNCT IDPhase
1Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of BoneUnknown statusNCT00445575Phase 2, Phase 3
2A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright SyndromeCompletedNCT00017927Phase 3
3TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONEUnknown statusNCT01791842Phase 2
4Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright SyndromeCompletedNCT00001728Phase 2
5Testolactone for the Treatment of Girls With LHRH Resistant Precocious PubertyCompletedNCT00001181Phase 2
6Arimidex in McCune Albright SyndromeCompletedNCT00055302Phase 2
7PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright SyndromeRecruitingNCT02743377Phase 1, Phase 2
8Faslodex in McCune Albright SyndromeActive, not recruitingNCT00278915Phase 2
9Effects of Letrozole on Precocious Puberty Due to McCune Albright SyndromeCompletedNCT00006174Phase 1
10Histamine Responsiveness in McCune-Albright SyndromeUnknown statusNCT00318097
11Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright SyndromeCompletedNCT00001973
12Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright SyndromeCompletedNCT00001851
13The Influence of Bisphosphonates in the Oral Cavity in ChildrenCompletedNCT00402064
14Natural History of Cherubism Observational StudyCompletedNCT01916772
15Interest of Serum Periostin Dosage in Patients With Bone Fibrous DysplasiaRecruitingNCT02868645
16Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and McCune-Albright SyndromeRecruitingNCT00001727
17Genetic and Functional Analysis of CherubismRecruitingNCT01630447

Search NIH Clinical Center for Fibrous Dysplasia

Genetic Tests for Fibrous Dysplasia

About this section

Anatomical Context for Fibrous Dysplasia

About this section

MalaCards organs/tissues related to Fibrous Dysplasia:

36
Bone, Bone marrow, Myeloid, B cells, Tongue, Pituitary, Testes

Publications for Fibrous Dysplasia

About this section

Articles related to Fibrous Dysplasia:

(show top 50)    (show all 766)
idTitleAuthorsYear
1
Prevalence of Different Forms and Involved Bones of Craniofacial Fibrous Dysplasia. (27922965)
2017
2
Functional and radiological outcomes of a minimally invasive surgical approach to monostotic fibrous dysplasia. (28057011)
2017
3
Fibrous Dysplasia Mimicking Malignancy on 68Ga-DOTATATE PET/CT. (28072620)
2017
4
Orbitocranial Fibrous Dysplasia: Outcome of Radical Resection and Immediate Reconstruction With Titanium Mesh and Pericranial Flap. (28005795)
2016
5
Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia. (27649526)
2016
6
Malignant transformation of polyostotic fibrous dysplasia with aberrant keratin expression. (27771377)
2016
7
Use of Zoledronic Acid in Paediatric Craniofacial Fibrous Dysplasia. (27747122)
2016
8
Fibrous dysplasia of bone: craniofacial and dental implications. (27493082)
2016
9
Three-Dimensional Printing of Reduction Template in the Contouring of Craniofacial Fibrous Dysplasia. (27513769)
2016
10
A rare location for fibrous dysplasia. The middle turbinate. (26898761)
2016
11
Craniofacial Fibrous Dysplasia: Retrospective Study on the Relationship Between the Tumor Volume Changes and the Circulating Serum Calcitonin and Serum Alkaline Phosphatase. (27922893)
2016
12
Ureter and Nerve Root Compression Secondary to Expansile Fibrous Dysplasia of the Transverse Process. (26866323)
2016
13
Conversion of Aneurysmal Bone Cyst into Fibrous Dysplasia: A Rare Pediatric Case Report. (27408470)
2016
14
Reply: Fibrous Dysplasia: Management of the Optic Canal. (26890521)
2016
15
Surgical Management of Polyostotic Craniofacial Fibrous Dysplasia: Long-Term Outcomes and Predictors for Postoperative Regrowth. (27219238)
2016
16
Fibrous Dysplasia Presenting as a Cold Spot in 18F-FLT PET/CT Imaging. (27055128)
2016
17
Fibrous dysplasia with secondary osteosarcoma - A rare presentation of a common disease. (27147164)
2016
18
A Rare Case of Monostotic Spinal Fibrous Dysplasia Mimicking Solitary Metastatic Lesion of Thyroid Carcinoma. (27540330)
2016
19
Fibrous dysplasia. Clinical review and therapeutic management. (27765282)
2016
20
Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia. (27894323)
2016
21
Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw. (27137436)
2016
22
Osteosarcoma of the Mandible Arising in Fibrous Dysplasia-A Case Report. (27425882)
2016
23
Recurrent Monostotic Fibrous Dysplasia in the Mandible. (27340572)
2016
24
Orbitocranial Fibrous Dysplasia: Outcome of Radical Resection and Immediate Reconstruction With Titanium Mesh and Pericranial Flap. (27617807)
2016
25
Monostotic fibrous dysplasia of the metacarpal: a case report. (28050548)
2016
26
Fibrous dysplasia of the maxilla in an elderly female: Case report on a 14-year quiescent phase. (28035304)
2016
27
Prognostic Factors From an Epidemiologic Evaluation of Fibrous Dysplasia of Bone in a Modern Cohort: The FRANCEDYS Study. (27340799)
2016
28
Differentiating Hyperostotic Temporal Bone Meningioma En Plaque and Fibrous Dysplasia on Computed Tomographic Imaging. (27585392)
2016
29
Simultaneous decompression of the orbital lateral wall and optic canal for fibrous dysplasia in early adolescence. (27375988)
2016
30
Fibrous Dysplasia of the Temporal Bone with External Auditory Canal Stenosis and Secondary Cholesteatoma. (27340999)
2016
31
Connection of a hip prosthesis and an intramedullary nail as a special solution in a subtrochanteric femoral fracture with fibrous dysplasia. (27105140)
2016
32
What Is the Role of Allogeneic Cortical Strut Grafts in the Treatment of Fibrous Dysplasia of the Proximal Femur? (27020436)
2016
33
Application of Reverse Engineering Template for the Correction of Asymmetric Deformity of Maxillofacial Fibrous Dysplasia. (26900746)
2016
34
CORR Insights (Ar) : What Is the Role of Allogeneic Cortical Strut Grafts in the Treatment of Fibrous Dysplasia of the Proximal Femur? (27106129)
2016
35
Odontogenic Sinusitis Caused by an Inflammation of a Dentigerous Cyst and Subsequent Finding of a Fibrous Dysplasia. A Case Report. (28077969)
2016
36
Pseudomyogenic hemangioendothelioma secondary to fibrous dysplasia of the left lower extremity in a 14-year-old female: a case report. (27468782)
2016
37
Erratum to: What Is the Role of Allogeneic Cortical Strut Grafts in the Treatment of Fibrous Dysplasia of the Proximal Femur? (27084715)
2016
38
Craniospinal Polyostotic Fibrous Dysplasia, Aneurysmal Bone Cysts, and Chiari Type 1 Malformation Coexistence in a Patient with McCune-Albright Syndrome. (27161212)
2016
39
Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives. (27492469)
2016
40
Fibrocartilaginous Dysplasia of the Bone: A Rare Variant of Fibrous Dysplasia. (26918216)
2016
41
Polyostotic Fibrous Dysplasia in McCune-Albright Syndrome Demonstrated on 68Ga-DOTATATE PET/CT. (27740949)
2016
42
Inhibition of fibrous dysplasia via blocking GsI+ with suramin sodium loaded with an alendronate-conjugated polymeric drug delivery system. (27180636)
2016
43
Lack of scintigraphic response of fibrous dysplasia to bisphosphonate treatment. (27411478)
2016
44
Fibrous Dysplasia: Management of the Optic Canal. (26890512)
2016
45
Headache Attributed to Fibrous Dysplasia of the Ethmoid Bone Mimicking Menstrual Migraine Without Aura. (27213743)
2016
46
Maxillofacial fibrous dysplasia: a diagnostic challenge. (27358102)
2016
47
McCune Albright syndrome - association of fibrous dysplasia, cafAc-au-lait skin spots and hyperthyroidism - case report. (27857528)
2016
48
Celecoxib treatment of fibrous dysplasia (FD) in a human FD cell line and FD-like lesions in mice with protein kinase A (PKA) defects. (27498419)
2016
49
An Atypical Presentation of Multiple Central Osteomas Mimicking Craniofacial Fibrous Dysplasia - A Pictorial Essay. (28050513)
2016
50
Pro-fibrotic effects of PFKFB4-mediated glycolytic reprogramming in fibrous dysplasia. (27614159)
2016

Variations for Fibrous Dysplasia

About this section

Expression for genes affiliated with Fibrous Dysplasia

About this section
Search GEO for disease gene expression data for Fibrous Dysplasia.

Pathways for genes affiliated with Fibrous Dysplasia

About this section

GO Terms for genes affiliated with Fibrous Dysplasia

About this section

Cellular components related to Fibrous Dysplasia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1endosome lumenGO:003190410.4GH1, PRL
2vesicleGO:00319829.5BGLAP, IBSP, SPARC
3extracellular spaceGO:00056157.9BGLAP, CALCA, FGF23, GH1, IBSP, IGF1
4extracellular regionGO:00055767.3BGLAP, CALCA, FGF23, GH1, GNAS, IBSP

Biological processes related to Fibrous Dysplasia according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1cellular response to vitamin DGO:007130510.6BGLAP, FGF23
2regulation of bone mineralizationGO:003050010.6BGLAP, FGF23
3biomineral tissue developmentGO:003121410.6BGLAP, IBSP
4response to gravityGO:000962910.4BGLAP, SPARC
5positive regulation of insulin-like growth factor receptor signaling pathwayGO:004356810.4GH1, IGF1
6positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.4GH1, IGF1
7JAK-STAT cascade involved in growth hormone signaling pathwayGO:006039710.3GH1, PRL
8positive regulation of JAK-STAT cascadeGO:004642710.3GH1, PRL
9regulation of multicellular organism growthGO:004001410.3IGF1, PRL
10bone developmentGO:006034810.3BGLAP, GNAS, SPARC
11cellular response to growth factor stimulusGO:007136310.2BGLAP, IBSP, SPARC
12response to ethanolGO:004547110.0BGLAP, PRL, SPARC
13skeletal system developmentGO:00015019.5BGLAP, GNAS, IGF1
14cellular protein metabolic processGO:00442679.5CALCA, FGF23, IGF1, PRL
15response to heatGO:00094089.5CALCA, IGF1, SST
16response to drugGO:00424939.5BGLAP, GNAS, PRL, SST

Molecular functions related to Fibrous Dysplasia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1growth factor activityGO:000808310.0FGF23, GH1, IGF1
2insulin-like growth factor receptor bindingGO:00051599.7GNAS, IGF1
3prolactin receptor bindingGO:00051489.6GH1, PRL
4hormone activityGO:00051798.4CALCA, GH1, IGF1, PRL, SST

Sources for Fibrous Dysplasia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet